

# State of New Product Development (As of April 24, 2026)

- If the product is being developed in multiple countries, including the US, "Global" is indicated in "Region/Country".
- When "Region/Country" is "Global", the most advanced stage of development among all regions/countries is indicated.
- If the "Stage" is filed and after, "Region/Country" is, in principle, Japan, the US, Europe, China, and Asia (excluding Japan and China). And not all region/countries are listed.
- ○ in "Changes" indicates changes from the previous announcement (as of January 23, 2026).

## Central nervous system

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-210 (Roluperidone)	5-HT2A/Sigma2 receptor antagonist	Schizophrenia	US	Filed		Licensed to Minerva Neurosciences (US)
			Europe	Phase 3		
ND0612 (Levodopa/Carbidopa)	Continuous SC pump	Parkinson's disease	Global	Phase 3		In-house
			US	Filed		
			Europe	Filed		
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody	Myasthenia gravis	Japan	Filed		Licensed from Amgen (US) and co-developed
MT-3921 (Unasnemab)	Anti-RGMA antibody	Spinal cord injury	Global	Phase 2		Co-discovered with Osaka University (Japan)
		HTLV-1 associated myelopathy	Japan	Phase 1		

## Immuno-inflammation

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody	Systemic sclerosis	Japan	Phase 3		Licensed from Amgen (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist	Erythropoietic protoporphyria, X-Linked protoporphyria	Global	Phase 3		In-house
		Systemic sclerosis	Global	Phase 2		
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody	ANCA associated vasculitis	Japan	Phase 1		In-house
MT-3534	Antibody	Autoimmune disease	Japan	Phase 1		Co-discovered with Pharma Foods International (Japan)

## Oncology

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-2111 (Loncastuximab tesirine)	Anti-CD19 antibody drug conjugate	Relapsed/Refractory diffuse large B-cell lymphoma (monotherapy)	Japan	Phase 1/2		Licensed from ADC Therapeutics (Switzerland)
		Relapsed/Refractory diffuse large B-cell lymphoma (with rituximab)	Japan	Phase 3		Licensed from ADC Therapeutics (Switzerland) and co-developed (Global study ongoing)
MT-4561	BRD4 degraders	Advanced solid tumors	Global	Phase 1/2		In-house

## Others

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-2412 CANALIA (teneligliptin, canagliflozin)	Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor	Type 2 diabetes mellitus	Asia	Filed		In-house